Want to see AU:RGT full AI Analyst Report?
Top Page
Argent Biopharma
(Sydney:RGT)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.03
â–¼(-25.00% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by very weak financial performance (sharp revenue contraction, negative gross profit, persistent large losses, negative equity, and ongoing cash burn). Technical indicators also lean bearish with the price below key moving averages and negative MACD. Valuation is constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Reduced Cash Burn
The reduction in operating cash outflow provides a limited improvement in near-term funding pressure. If maintained, better cash discipline could extend liquidity and reduce the pace of external financing needs, although operations remain far from self-funding.
Negative Factors
Revenue and Profit Collapse
The sharp revenue contraction and move into negative gross profit indicate that the current commercial base is not supporting the cost structure. Deep operating and net losses weaken reinvestment capacity and make a durable earnings recovery dependent on substantial business improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced Cash Burn
The reduction in operating cash outflow provides a limited improvement in near-term funding pressure. If maintained, better cash discipline could extend liquidity and reduce the pace of external financing needs, although operations remain far from self-funding.
Read all positive factors
Argent Biopharma (RGT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.85M
Dividend YieldN/A
Average Volume (3M)537.26K
Price to Earnings (P/E)―
Beta (1Y)-1.26
Revenue Growth17.56%
EPS Growth75.11%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.14
Shares Outstanding116,609,580
10 Day Avg. Volume175,750
30 Day Avg. Volume537,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.33
Price to Sales (P/S)19.37
P/FCF Ratio-0.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Argent Biopharma Business Overview & Revenue Model
Company Description
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatment...
How the Company Makes Money
null...
Argent Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 433.48K | 161.19K | 583.45K | 891.08K | 3.39M | 4.73M |
| Gross Profit | -211.29K | -204.21K | 446.32K | 203.70K | 1.45M | 1.81M |
| EBITDA | -9.76M | -7.23M | -17.00M | -15.77M | -20.04M | -16.70M |
| Net Income | -4.40M | -7.71M | -17.84M | -17.53M | -20.82M | -16.77M |
Balance Sheet | ||||||
| Total Assets | 2.01M | 1.29M | 2.47M | 10.79M | 9.88M | 23.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.53M | 141.46K | 1.02M | 702.87K | 239.82K | 1.79M |
| Total Debt | 8.91M | 9.59M | 8.29M | 1.04M | 575.14K | 4.39M |
| Total Liabilities | 10.46M | 10.74M | 11.10M | 16.61M | 18.02M | 13.66M |
| Stockholders Equity | -8.44M | -9.45M | -8.63M | -5.15M | -7.51M | 11.23M |
Cash Flow | ||||||
| Free Cash Flow | -8.92M | -4.03M | -9.28M | -14.80M | -12.18M | -14.85M |
| Operating Cash Flow | -8.91M | -4.03M | -9.28M | -14.66M | -11.99M | -12.16M |
| Investing Cash Flow | 209.95K | -721.00 | 208.83K | -140.12K | 606.20K | -1.11M |
| Financing Cash Flow | 9.77M | 3.14M | 9.39M | 15.27M | 9.73M | 9.74M |
Argent Biopharma Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Negative
43.13
Neutral
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RGT, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.13 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RGT.
Argent Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$57.96M | -15.22 | -1.67% | ― | 15.21% | -141.82% | |
53 Neutral | AU$8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.25M | -2.99 | -9.80% | 10.00% | 5.74% | -222.22% | |
50 Neutral | AU$3.51M | -0.79 | -50.35% | ― | -4.87% | -9.78% | |
40 Underperform | AU$3.85M | -0.24 | 118.54% | ― | 17.56% | 75.11% | |
39 Underperform | AU$18.75M | -5.07 | 4388.00% | ― | -19.29% | 62.42% |
* Healthcare Sector Average
AU:RGT
Argent Biopharma
0.03
-0.08
-71.30%
AU:EXL
Elixinol Wellness
0.02
<0.01
7.14%
AU:CAN
Cann Group
0.01
>-0.01
-9.09%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-41.67%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-30.00%
AU:VIT
Cronos Australia Ltd.
0.02
-0.05
-70.59%
Argent Biopharma Corporate Events
Argent Biopharma Cancels Over 5.5 Million Convertible Notes
Sep 1, 2026
Argent Biopharma Limited has updated the market on changes to its capital structure, notifying the cessation of a series of convertible notes listed under the ASX code RGTAAA. The company reported that 5,502,532 of these convertible securities hav...
Argent BioPharma Narrows Annual Loss After Restructuring and Cost Controls
Aug 31, 2026
Argent BioPharma reported revenue of $161,187 for the year ended 30 June 2026, an 11% decline from the prior year, while its net loss narrowed markedly to $7.7 million from $17.8 million as tighter expenditure discipline took hold. The board did n...
Argent Biopharma Details Governance Compliance in ASX Filing
Aug 31, 2026
Argent Biopharma has lodged its Appendix 4G and confirmed that its corporate governance statement for the year ended 30 June 2026 is available on its website, in line with ASX Listing Rules. The filing, approved by the board as of 31 August 2026, ...
Argent BioPharma Secures FDA-CVM INAD for CannEpil Veterinary Cancer-Pain Program
Aug 26, 2026
Argent BioPharma’s CannEpil platform is being extended into veterinary healthcare through a global licensing arrangement with Endovia Health Sciences, with Lupvindol Biosciences leading scientific and regulatory development in the U.S. The i...
Argent Biopharma Plans Options and Convertible Notes Issue to Bolster Funding
Aug 10, 2026
Argent Biopharma Limited has lodged an Appendix 3B with the ASX detailing a proposed issue of new securities as part of a placement or similar capital raising. The company plans to issue up to 2,010,724 unlisted options exercisable at A$0.09325 wi...
Argent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program
Aug 5, 2026
Argent BioPharma’s licensing partner Splash Beverage Group has launched a U.S. veterinary pharmaceutical development program for CannEpil®, in collaboration with Lupvindol Biosciences, marking the product’s expansion into animal h...
Argent Biopharma Options Expire Unexercised, Simplifying Capital Structure
Aug 3, 2026
Argent Biopharma has announced the cessation of 181,422 options with an exercise price of $3.00, which expired on 31 July 2026 without being exercised or converted. The expiry reduces the company’s pool of outstanding convertible securities,...
Argent BioPharma Extends CannEpil Licence into Global Veterinary Market
Jul 31, 2026
Argent BioPharma has amended its exclusive global licensing agreement for CannEpil® to extend beyond human neurological uses into veterinary healthcare, creating a second commercial pathway in the global animal health market. The company will...
Argent Biopharma Cuts Debt with CannEpil Deal and Expands Veterinary Pipeline
Jul 27, 2026
Argent Biopharma has signed an exclusive global licensing agreement with Splash Beverage Group for CannEpil®, its cannabinoid therapy for drug-resistant epilepsy, in a deal that extinguishes US$5.5 million in secured convertible debt without ...
Argent BioPharma Secures Additional Convertible Note Funding and Updates Capital Structure
Jul 14, 2026
Argent BioPharma has drawn a further A$350,000 under its existing convertible securities financing agreement with U.S.-based institutional investors managed by C/M Capital Partners. In return, the company will issue 385,000 new unquoted convertibl...
Argent Biopharma Issues 385,000 New Convertible Notes on ASX
Jul 14, 2026
Argent Biopharma Limited has notified the market of the issuance of 385,000 unquoted convertible notes, designated under the ASX security code RGTAAA, with an issue date of July 14, 2026. The new notes expand the company’s convertible debt s...
Argent Biopharma Plans New Unlisted Options Issue on ASX
Jul 14, 2026
Argent Biopharma Limited has notified the ASX of a proposed issue of new unlisted options as part of a placement or similar capital initiative. The options will be exercisable at A$0.0511 and will expire 36 months from the date of issue, with a ma...
Argent BioPharma Draws A$350,000 Under Convertible Funding Deal
Jul 14, 2026
Argent BioPharma Ltd., a clinical-stage biopharmaceutical company specialising in nano-engineered therapeutics for neurological and immune-mediated disorders, generates revenue from its lead assets CannEpil and CimetrA. These programs, supported b...
Argent Biopharma Seeks ASX Quotation for 5.5 Million New Shares
Jul 8, 2026
Argent Biopharma Limited has applied for ASX quotation of 5,500,000 new ordinary fully paid shares under the ticker RGT. The securities were issued on July 8, 2026, and this filing formalizes their admission to trading on the Australian Securities...
Argent BioPharma Strikes Global CannEpil Licensing Deal to Wipe Out Secured Debt
Jul 6, 2026
Argent BioPharma has entered a binding agreement to grant Splash Beverage Group exclusive global licensing rights for CannEpil, its cannabinoid therapy for drug-resistant epilepsy. Argent will retain ownership of all existing and future CannEpil i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.